All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

@dr.karanr's GLP-1 forever question, fact-checked

Dr Karan Rajan

TikTok creator

3.1M viewsWatch on TikTok→

Quick answer

GLP-1 receptor agonists produce significant weight loss during treatment, but discontinuation typically results in substantial weight regain driven by hormonal and metabolic compensation, not habit failure alone. The STEP 4 and SURMOUNT-4 trials both demonstrate that the majority of weight lost returns within 12 months of stopping semaglutide or tirzepatide, even with lifestyle support. Patients and clinicians should treat obesity as a chronic condition and discuss long-term medication strategy rather than planning for an exit by default.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @dr.karanr actually say?

In a video that's racked up 3.1 million views, Dr. Karan Rajan argued that GLP-1 medications don't "fix" weight loss but instead "change the conditions inside your brain and gut" to make healthy habits easier. He split patients into two camps: those with short-term, situational weight gain who might taper off, and those with chronic obesity as a biological condition who may need these drugs indefinitely. His closing line, that "stopping the GLP-1s doesn't cause the weight regain, it's stopping the habit," is doing a lot of heavy lifting here, and deserves scrutiny.

The framing is mostly responsible. He's not selling miracles. He's not claiming semaglutide cures anything. He's trying to reframe obesity as a chronic disease rather than a character flaw, which is a legitimate clinical position. But some of the nuance gets lost in the 60-second format.

Does the science back this up?

The core claim, that obesity is a chronic biological condition requiring long-term intervention, is well-supported. The evidence on what happens when you stop GLP-1s is also pretty clear, and it complicates his framing slightly.

The STEP 4 trial (Rubino et al., 2021, New England Journal of Medicine) followed patients who stopped semaglutide after 20 weeks. Within a year, two-thirds of the weight lost came back. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar regain patterns after stopping tirzepatide. These aren't edge cases. Weight regain after discontinuation is the norm, not the exception.

His point about GLP-1s altering gut-brain signaling is also grounded in real biology. GLP-1 receptors are expressed in the hypothalamus and brainstem, and research from Müller et al. (2022, Nature Reviews Endocrinology) confirms these drugs reduce appetite partly through central nervous system pathways. That part checks out.

What did they get wrong (or right)?

The biggest issue is the claim that "stopping the GLP-1s doesn't cause the weight regain, it's stopping the habit." This is partially true but potentially misleading to a mass audience.

The data from STEP 4 and SURMOUNT-4 shows that weight regain happens even in people who maintain lifestyle changes. The biology of obesity, specifically the reduction in leptin and increase in ghrelin that follows weight loss, doesn't care how many grams of protein you're eating. Tremblay and Chaput (2009, Obesity Reviews) documented this hormonal compensation response years before GLP-1s were mainstream. Blaming regain primarily on "stopping the habit" lets the drug off the hook in a way the clinical data doesn't fully support.

What he got right: the chronic disease framing is accurate and reduces stigma. His comparison to thyroid conditions and blood pressure medications is a fair analogy. And his emphasis on fiber, protein, resistance training, and sleep as non-negotiables is consistent with evidence-based guidelines from the American College of Lifestyle Medicine.

What should you actually know?

If you're considering stopping a GLP-1 medication, the conversation has to happen with a prescribing clinician, not a TikTok comment section. The reasons to stop, cost, side effects, pregnancy, reaching a stable weight, are real. But the expectation that habits alone will hold all the weight loss is not well-supported by clinical data for most people with chronic obesity.

The situational vs. chronic framing he offers is a useful starting point, but it's not a clean binary. Menopause-related weight gain, for instance, often involves the same hormonal dysregulation he associates with chronic obesity, and the research on GLP-1 use in perimenopause is still early. Escalante et al. (2023, Menopause) found significant metabolic overlap between menopause-related and obesity-related weight gain that complicates a simple short-term vs. long-term split.

The honest answer to "do you need GLP-1s forever?" is: many people do, and that's not a failure. For others, a structured taper with close monitoring and realistic expectations is possible. Neither outcome is guaranteed by habits alone.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @dr.karanr's GLP-1 forever question, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@dr.karanr's GLP-1 forever question, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

GLP-1 receptor agonists produce significant weight loss during treatment, but discontinuation typically results in substantial weight regain driven by hormonal and metabolic compensation, not habit failure alone.

FormBlends verdict

GLP-1 receptor agonists produce significant weight loss during treatment, but discontinuation typically results in substantial weight regain driven by hormonal and metabolic compensation, not habit failure alone. The STEP 4 and SURMOUNT-4 trials both demonstrate that the majority of weight lost returns within 12 months of stopping semaglutide or tirzepatide, even with lifestyle support. Patients and clinicians should treat obesity as a chronic condition and discuss long-term medication strategy rather than planning for an exit by default.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists produce significant weight loss during treatment, but discontinuation typically results in substantial weight regain driven by hormonal and metabolic compensation, not habit failure alone. The STEP 4 and SURMOUNT-4 trials both demonstrate that the majority of weight lost returns within 12 months of stopping semaglutide or tirzepatide, even with lifestyle support. Patients and clinicians should treat obesity as a chronic condition and discuss long-term medication strategy rather than planning for an exit by default.
  • The STEP 4 trial (Rubino et al., 2021, NEJM) found that patients who stopped semaglutide regained approximately two-thirds of their lost weight within 12 months, even with continued lifestyle support.
  • GLP-1 receptors are expressed in the hypothalamus and brainstem, meaning appetite suppression from these drugs has a real neurological basis, not just a gut effect.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The STEP 4 trial (Rubino et al., 2021, NEJM) found that patients who stopped semaglutide regained approximately two-thirds of their lost weight within 12 months, even with continued lifestyle support.
  • GLP-1 receptors are expressed in the hypothalamus and brainstem, meaning appetite suppression from these drugs has a real neurological basis, not just a gut effect.
  • The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) confirmed similar weight regain patterns after stopping tirzepatide, suggesting discontinuation-driven regain is a class-wide phenomenon.
  • Hormonal compensation after weight loss, including lower leptin and higher ghrelin, occurs regardless of diet quality and is a documented driver of regain independent of behavior (Tremblay and Chaput, 2009, Obesity Reviews).
  • The American Medical Association classified obesity as a chronic disease in 2013, supporting the clinical case for long-term pharmacological management in appropriate patients.
  • Menopause-related weight gain shares significant metabolic overlap with chronic obesity presentations, making a clean short-term vs. long-term GLP-1 use distinction difficult to apply in practice.
  • Lifestyle interventions including resistance training and high-protein diets help preserve lean mass but are not reliably sufficient to prevent weight regain after GLP-1 discontinuation in patients with chronic obesity.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr Karan Rajan · TikTok creator

3.1M views on this video

GLP-1 forever? @Natalie Haytayan

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr Karan Rajan, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.